BP-1-102 manufacturers
- BP-1-102
-
- $33.00 / 1mg
-
2026-04-14
- CAS:1334493-07-0
- Min. Order:
- Purity: 99.25%
- Supply Ability: 10g
|
| | BP-1-102 Basic information |
| Product Name: | BP-1-102 | | Synonyms: | BP-1-102;4-(N-(4-Cyclohexylbenzyl)-2-(2,3,4,5,6-pentafluoro-N-methylphenylsulfonamido)acetamido)-2-hydr;STAT3 Inhibitor XVIII, BP-1-102;BP-1-102; BP1-102; BP 1-102.;4-(N-(4-cyclohexylbenzyl)-2-(2,3,4,5,6-pentafluoro-N-methylphenylsulfonamido)acetamido)-2-hydroxybenzoic acid;STAT3 Inhibitor XVIII;STAT3 INHIBITOR XVIII;BP1-102;BP 1-102;Benzoic acid, 4-[[(4-cyclohexylphenyl)methyl][2-[methyl[(2,3,4,5,6-pentafluorophenyl)sulfonyl]amino]acetyl]amino]-2-hydroxy- | | CAS: | 1334493-07-0 | | MF: | C29H27F5N2O6S | | MW: | 626.59 | | EINECS: | | | Product Categories: | API | | Mol File: | 1334493-07-0.mol |  |
| | BP-1-102 Chemical Properties |
| Boiling point | 749.2±70.0 °C(Predicted) | | density | 1.474±0.06 g/cm3(Predicted) | | storage temp. | Inert atmosphere,Store in freezer, under -20°C | | solubility | DMSO:15.0(Max Conc. mg/mL);23.9(Max Conc. mM) | | pka | 3.15±0.10(Predicted) | | form | A crystalline solid | | color | White to off-white | | InChIKey | WNVSFFVDMUSXSX-UHFFFAOYSA-N | | SMILES | C(O)(=O)C1=CC=C(N(CC2=CC=C(C3CCCCC3)C=C2)C(CN(C)S(C2=C(F)C(F)=C(F)C(F)=C2F)(=O)=O)=O)C=C1O |
| WGK Germany | WGK 2 | | Storage Class | 11 - Combustible Solids |
| | BP-1-102 Usage And Synthesis |
| Uses | BP-1-102 is a potent and selective STAT3 inhibitor. STAT3 is a cytoplasmic transcription factor that induces the expression of genes related to tumorigenesis. BP 1-102 exhibits antitumor activity against Waldenstrom macroglobulinemia, a rare form of B cell non-Hodgkin lymphoma. | | Biological Activity | Primary Target
Stat3 | | Synthesis | General method: Benzyl-protected salicylic acid (1 eq.) was dissolved in a stirred solvent mixture of methanol/tetrahydrofuran (1:1, v/v, 0.1 M). After thorough degassing, 10% palladium/carbon catalyst (10 mg/mmol) was cautiously added. The solution was bubbled with hydrogen gas for 5 minutes, followed by continuous stirring of the reaction under hydrogen atmosphere for 3 hours. Upon completion of the reaction, the hydrogen was removed, the palladium catalyst was removed by filtration, and the filtrate was concentrated under reduced pressure. | | in vivo | Mice therapeutically given BP-1-102, an orally bioavailable compound targeting STAT3/NF-kB activation and cross-talk, exhibit reduced colon tumorigenesis and diminished expression of STAT3/NF-kB-activating cytokines in the neoplastic areas[2]. BP-1-102 is orally bioavailable and that the agent accumulates in tumor tissues at levels sufficient to inhibit aberrantly active Stat3 functions and inhibit tumor growth[1]. | | IC 50 | STAT3: 6.8 μM (IC50) | | References | [1] Bioorganic and Medicinal Chemistry Letters, 2011, vol. 21, # 18, p. 5605 - 5609
[2] ACS Medicinal Chemistry Letters, 2013, vol. 4, # 11, p. 1102 - 1107
[3] Journal of Medicinal Chemistry, 2013, vol. 56, # 18, p. 7190 - 7200 |
| | BP-1-102 Preparation Products And Raw materials |
|